Cel-sci Corp (CVM)
$1.46
Insights on Cel-sci Corp
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 91.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 341.4%
Performance
- $1.44$1.47$1.46
1.37%
Downside
Day's Volatility :2.04%
Upside
0.68%
- $1.04$3.23$1.46
28.77%
Downside
52 Weeks Volatility :67.8%
Upside
54.8%
Returns
| Period | Cel-sci Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -45.52% | 2.0% | 0.0% |
6 Months | 3.55% | 11.7% | 0.0% |
1 Year | -39.17% | 5.8% | 1.3% |
3 Years | -94.18% | 14.2% | -22.1% |
Highlights
Market Capitalization | 81.5M |
Book Value | $0.25 |
Earnings Per Share (EPS) | -0.69 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.47 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -51.71% |
Return On Equity TTM | -158.25% |
Revenue TTM | 28.6K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -62.7% |
Gross Profit TTM | -25.4M |
EBITDA | -28.1M |
Diluted Eps TTM | -0.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.72 |
EPS Estimate Next Year | -0.49 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | -0.14 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 480.14%
Technicals Summary
Sell
Neutral
Buy
Cel-sci Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cel-sci Corp | -10.43% | 3.55% | -39.17% | -94.18% | -79.02% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cel-sci Corp | NA | NA | 0.0 | -0.72 | -1.58 | -0.52 | NA | 0.25 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cel-sci Corp | Buy | $81.5M | -79.02% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Corporate Announcements
Cel-sci Corp Earnings
Cel-sci Corp’s price-to-earnings ratio stands at None
Read More
Company Information
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Organization | Cel-sci Corp |
Employees | 0 |
CEO | Mr. Geert R. Kersten Esq. |
Industry | Health Technology |
